AbbVie Pushes Greater Flexibility With Oral Migraine Preventative Atogepant

 
• By Joseph Haas

With an FDA approval decision for preventing episodic migraines expected during Q3, atogepant would add an oral CGRP antagonist to classmate Ubrelvy for acute attacks and Botox for prevention of chronic episodes.

Diagnosis - Migraine. Medical Concept with Red Pills, Injections and Syringe. Selective Focus. 3D Render.
AbbVie hopes it will have a third approved migraine therapy by year's end

More from Strategy

More from Business